Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Status:
Terminated
Trial end date:
2012-12-15
Target enrollment:
Participant gender:
Summary
This study is to determine if the combination regimen of tivantinib with erlotinib will
improve overall survival relative to erlotinib alone in subjects with locally advanced or
metastatic non-squamous, non-small cell lung cancer who have received 1 or 2 prior systemic
anti-cancer therapies.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc.
Collaborators:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)